List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5821570/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Evaluation of cannabinoids concentration and stability in standardized preparations of cannabis tea and cannabis oil by ultra-high performance liquid chromatography tandem mass spectrometry. Clinical Chemistry and Laboratory Medicine, 2017, 55, 1555-1563.	2.3	99
2	Assessment of exposure to opiates and cocaine during pregnancy in a Mediterranean city: Preliminary results of the "Meconium Project― Forensic Science International, 2005, 153, 59-65.	2.2	93
3	Simultaneous analysis of frequently used licit and illicit psychoactive drugs in breast milk by liquid chromatography tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 309-316.	2.8	86
4	Liquid chromatography/electrospray ionization tandem mass spectrometry assay for determination of nicotine and metabolites, caffeine and arecoline in breast milk. Rapid Communications in Mass Spectrometry, 2007, 21, 2693-2703.	1.5	82
5	Ethyl glucuronide and ethyl sulfate in meconium and hair-potential biomarkers of intrauterine exposure to ethanol. Forensic Science International, 2010, 196, 74-77.	2.2	81
6	Method Development in Forensic Toxicology. Current Pharmaceutical Design, 2018, 23, 5455-5467.	1.9	70
7	A rapid and simple procedure for the determination of cannabinoids in hemp food products by gas chromatography-mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2005, 36, 939-946.	2.8	63
8	Development and Validation of a High-Performance Liquid Chromatographyâ^'Mass Spectrometry Assay for Determination of Amphetamine, Methamphetamine, and Methylenedioxy Derivatives in Meconium. Analytical Chemistry, 2004, 76, 2124-2132.	6.5	62
9	Development and validation of a liquid chromatography–mass spectrometry assay for the determination of opiates and cocaine in meconium. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 794, 281-292.	2.3	60
10	New synthetic opioids in biological and non-biological matrices: AÂreview of current analytical methods. TrAC - Trends in Analytical Chemistry, 2018, 102, 1-15.	11.4	57
11	Liquid chromatography–tandem mass spectrometry for fatty acid ethyl esters in meconium: Assessment of prenatal exposure to alcohol in two European cohorts. Journal of Pharmaceutical and Biomedical Analysis, 2008, 48, 927-933.	2.8	56
12	High performance liquid chromatography-diode array and electrospray-mass spectrometry analysis of vardenafil, sildenafil, tadalafil, testosterone and local anesthetics in cosmetic creams sold on the Internet web sites. Journal of Pharmaceutical and Biomedical Analysis, 2009, 50, 362-369.	2.8	56
13	Evaluation of long-term stability of cannabinoids in standardized preparations of cannabis flowering tops and cannabis oil by ultra-high-performance liquid chromatography tandem mass spectrometry. Clinical Chemistry and Laboratory Medicine, 2018, 56, 94-96.	2.3	56
14	Assessment of Prenatal Exposure to Ethanol by Meconium Analysis: Results of an Italian Multicenter Study. Alcoholism: Clinical and Experimental Research, 2012, 36, 417-424.	2.4	55
15	Quantification of the plant-derived hallucinogen Salvinorin A in conventional and non-conventional biological fluids by gas chromatography/mass spectrometry afterSalvia divinorum smoking. Rapid Communications in Mass Spectrometry, 2005, 19, 1649-1656.	1.5	54
16	Liquid chromatography–atmospheric pressure ionization electrospray mass spectrometry determination of "hallucinogenic designer drugs―in urine of consumers. Journal of Pharmaceutical and Biomedical Analysis, 2008, 47, 335-342.	2.8	53
17	Prevalence of gestational exposure to cannabis in a Mediterranean city by meconium analysis. Acta Paediatrica, International Journal of Paediatrics, 2007, 96, 1734-1737.	1.5	49
18	Testing Ethylglucuronide in Maternal Hair and Nails for the Assessment of Fetal Exposure to Alcohol. Therapeutic Drug Monitoring, 2013, 35, 402-407.	2.0	48

#	Article	IF	CITATIONS
19	Ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC–MS/MS) for determination of GHB, precursors and metabolites in different specimens: Application to clinical and forensic cases. Journal of Pharmaceutical and Biomedical Analysis, 2017, 137, 123-131.	2.8	48
20	New vesicular ampicillin-loaded delivery systems for topical application: characterization, in vitro permeation experiments and antimicrobial activity. Journal of Controlled Release, 2004, 95, 67-74.	9.9	46
21	A rapid and simple procedure for the determination of ephedrine alkaloids in dietary supplements by gas chromatography–mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2006, 41, 1633-1641.	2.8	46
22	High-performance liquid chromatography–diode array and electrospray-mass spectrometry analysis of non-allowed substances in cosmetic products for preventing hair loss and other hormone-dependent skin diseases. Journal of Pharmaceutical and Biomedical Analysis, 2008, 48, 641-648.	2.8	43
23	Development and validation of a high-performance liquid chromatography–mass spectrometry assay for methylxanthines and taurine in dietary supplements. Journal of Pharmaceutical and Biomedical Analysis, 2005, 37, 499-507.	2.8	42
24	Liquid Chromatography With Tandem Mass Spectrometric Detection for the Measurement of Ethyl Glucuronide and Ethyl Sulfate in Meconium: New Biomarkers of Gestational Ethanol Exposure?. Therapeutic Drug Monitoring, 2008, 30, 725-732.	2.0	39
25	Liquid chromatography–electrospray ionization mass spectrometry determination of methylphenidate and ritalinic acid in conventional and non-conventional biological matrices. Journal of Pharmaceutical and Biomedical Analysis, 2009, 49, 434-439.	2.8	39
26	Quantification of Δ9-tetrahydrocannabinol and its Major Metabolites in Meconium by Gas Chromatographic-mass Spectrometric Assay: Assay Validation and Preliminary Results of the "Meconium Project― Therapeutic Drug Monitoring, 2006, 28, 700-706.	2.0	37
27	Population Baseline of Meconium Ethyl Glucuronide and Ethyl Sulfate Concentrations in Newborns of Nondrinking Women in 2 Mediterranean Cohorts. Therapeutic Drug Monitoring, 2010, 32, 359-363.	2.0	37
28	Antiretroviral Prophylaxis for Breastfeeding Transmission in Malawi: Drug Concentrations, Virological Efficacy and Safety. Antiviral Therapy, 2012, 17, 1511-1519.	1.0	37
29	Quantification of arecoline (areca nut alkaloid) in neonatal biological matrices by high-performance liquid chromatography/electrospray quadrupole mass spectrometry. Rapid Communications in Mass Spectrometry, 2003, 17, 1958-1964.	1.5	36
30	Fetal exposure to ethanol: relationship between ethyl glucuronide in maternal hair during pregnancy and ethyl glucuronide in neonatal meconium. Clinical Chemistry and Laboratory Medicine, 2016, 54, 427-35.	2.3	35
31	3,4-Methylenedioxymethamphetamine (MDMA) Intoxication in an Infant Chronically Exposed to Cocaine. Therapeutic Drug Monitoring, 2005, 27, 409-411.	2.0	34
32	On-site screening and GC–MS analysis of cocaine and heroin metabolites in body-packers urine. Journal of Pharmaceutical and Biomedical Analysis, 2008, 48, 383-387.	2.8	34
33	Ultra-high-pressure liquid chromatography tandem mass spectrometry determination of hallucinogenic drugs in hair of psychedelic plants and mushrooms consumers. Journal of Pharmaceutical and Biomedical Analysis, 2014, 100, 284-289.	2.8	34
34	A rapid and simple procedure for the determination of synephrine in dietary supplements by gas chromatography-mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2006, 41, 1468-1472.	2.8	33
35	Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi. Journal of Antimicrobial Chemotherapy, 2016, 71, 1027-1030.	3.0	32
36	Dilute and shoot ultra-high performance liquid chromatography tandem mass spectrometry (UHPLC–MS/MS) analysis of psychoactive drugs in oral fluid. Journal of Pharmaceutical and Biomedical Analysis, 2019, 170, 63-67.	2.8	32

#	Article	IF	CITATIONS
37	Development and validation of a gas chromatography–mass spectrometry assay for opiates and cocaine in human teeth. Journal of Pharmaceutical and Biomedical Analysis, 2006, 40, 662-668.	2.8	31
38	Neonatal Withdrawal Syndrome After Chronic Maternal Drinking of Mate. Therapeutic Drug Monitoring, 2007, 29, 127-129.	2.0	31
39	Simultaneous determination of zidovudine and nevirapine in human plasma by RP-LC. Journal of Pharmaceutical and Biomedical Analysis, 2002, 29, 1081-1088.	2.8	29
40	Pharmacokinetics of methylphenidate in oral fluid and sweat of a pediatric subject. Forensic Science International, 2010, 196, 59-63.	2.2	29
41	Identification and quantification of 11-nor-î"9-tetrahydrocannabinol-9-carboxylic acid glucuronide (THC-COOH-glu) in hair by ultra-performance liquid chromatography tandem mass spectrometry as a potential hair biomarker of cannabis use. Forensic Science International, 2015, 249, 47-51.	2.2	29
42	Identification and quantification of psychoactive drugs in whole blood using dried blood spot (DBS) by ultra-performance liquid chromatography tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2016, 128, 53-60.	2.8	29
43	Ultra-high-pressure liquid chromatography tandem mass spectrometry determination of antidepressant and anxiolytic drugs in neonatal meconium and maternal hair. Journal of Pharmaceutical and Biomedical Analysis, 2016, 118, 9-16.	2.8	28
44	Are False-Positive Phencyclidine Immunoassay Instant-View Multi-Test Results Caused by Overdose Concentrations of Ibuprofen, Metamizol, and Dextromethorphan?. Therapeutic Drug Monitoring, 2007, 29, 671-673.	2.0	27
45	Development and validation of a liquid chromatography–mass spectrometry assay for hair analysis of methylphenidate. Forensic Science International, 2008, 176, 42-46.	2.2	27
46	Correlation Between Methylphenidate and Ritalinic Acid Concentrations in Oral Fluid and Plasma. Clinical Chemistry, 2010, 56, 585-592.	3.2	27
47	Maternal hair testing to disclose self-misreporting in drinking and smoking behavior during pregnancy. Alcohol, 2018, 67, 1-6.	1.7	27
48	Development and validation of a liquid chromatography–tandem mass spectrometry assay for hair analysis of atomoxetine and its metabolites: Application in clinical practice. Forensic Science International, 2012, 218, 62-67.	2.2	24
49	Application of a validated high-performance liquid chromatography–mass spectrometry assay to the analysis of - and -hydroxybenzoylecgonine in meconium. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 820, 151-156.	2.3	23
50	Determination of arecoline (areca nut alkaloid) and nicotine in hair by high-performance liquid chromatography/electrospray quadrupole mass spectrometry. Rapid Communications in Mass Spectrometry, 2005, 19, 3416-3418.	1.5	23
51	Ultrasensitive detection of nicotine and cotinine in teeth by highâ€performance liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2008, 22, 2609-2612.	1.5	23
52	Rapid extraction, identification and quantification of drugs of abuse in hair by immunoassay and ultra-performance liquid chromatography tandem mass spectrometry. Clinical Chemistry and Laboratory Medicine, 2014, 52, 679-86.	2.3	23
53	Intoxication caused by new psychostimulants: analytical methods to disclose acute and chronic use of benzofurans and ethylphenidate. International Journal of Legal Medicine, 2017, 131, 1543-1553.	2.2	23
54	Chemsex intoxication involving sildenafil as an adulterant of GHB. Drug Testing and Analysis, 2017, 9, 956-959.	2.6	22

#	Article	IF	CITATIONS
55	Determination of atomoxetine and its metabolites in conventional and non-conventional biological matrices by liquid chromatography–tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2012, 60, 26-31.	2.8	21
56	Stability of cannabinoids in cannabis FM1 flowering tops and oil preparation evaluated by ultra-high performance liquid chromatography tandem mass spectrometry. Clinical Chemistry and Laboratory Medicine, 2019, 57, e165-e168.	2.3	19
57	Ultra-High Performance Liquid Chromatography-High Resolution Mass Spectrometry and High-Sensitivity Gas Chromatography-Mass Spectrometry Screening of Classic Drugs and New Psychoactive Substances and Metabolites in Urine of Consumers. International Journal of Molecular Sciences. 2021. 22. 4000.	4.1	19
58	Advances in the analysis of non-allowed pharmacologically active substances in cosmetic products. Journal of Pharmaceutical and Biomedical Analysis, 2011, 55, 842-847.	2.8	18
59	Breast Milk and Hair Testing to Detect Illegal Drugs, Nicotine, and Caffeine in Donors to a Human Milk Bank. Journal of Human Lactation, 2016, 32, 542-545.	1.6	18
60	Análisis segmentario del pelo para detectar la exposición crónica a drogas psicoactivas. Revista De Psicologia De La Salud, 2016, 28, 158.	0.5	17
61	Drugs of abuse in maternal hair and paired neonatal meconium: an objective assessment of foetal exposure to gestational consumption. Drug Testing and Analysis, 2016, 8, 864-868.	2.6	16
62	Usefulness of Sweat Testing for the Detection of Methylphenidate After Fast- and Extended-Release Drug Administration: A Pilot Study. Therapeutic Drug Monitoring, 2010, 32, 508-511.	2.0	15
63	Hair and urine testing to assess drugs of abuse consumption in couples undergoing assisted reproductive technology (ART). Forensic Science International, 2012, 218, 57-61.	2.2	15
64	Stability and Degradation Pathways of Different Psychoactive Drugs in Neat and in Buffered Oral Fluid. Journal of Analytical Toxicology, 2020, 44, 570-579.	2.8	15
65	Concentrations of atomoxetine and its metabolites in plasma and oral fluid from paediatric patients with attention deficit/hyperactivity disorder. Drug Testing and Analysis, 2013, 5, 446-452.	2.6	14
66	Assessment of Unsuspected Exposure to Drugs of Abuse in Children from a Mediterranean City by Hair Testing. International Journal of Environmental Research and Public Health, 2014, 11, 2288-2298.	2.6	14
67	UHPLC-HRMS and GC-MS Screening of a Selection of Synthetic Cannabinoids and Metabolites in Urine of Consumers. Medicina (Lithuania), 2020, 56, 408.	2.0	13
68	Determination of the Synthetic Cannabinoids JWH-122, JWH-210, UR-144 in Oral Fluid of Consumers by GC-MS and Quantification of Parent Compounds and Metabolites by UHPLC-MS/MS. International Journal of Molecular Sciences, 2020, 21, 9414.	4.1	12
69	Sweat testing for the detection of atomoxetine from paediatric patients with attention deficit/ hyperactivity disorder: application to clinical practice. Drug Testing and Analysis, 2013, 5, 191-195.	2.6	11
70	Magic truffles or Philosopher's stones: a legal way to sell psilocybin?. Drug Testing and Analysis, 2013, 5, 182-185.	2.6	11
71	Assay of Î ³ -glutamylcysteine synthetase activity in Plasmodium berghei by liquid chromatography with electrochemical detection. Journal of Pharmaceutical and Biomedical Analysis, 2001, 25, 759-765.	2.8	9
72	Assessment of licit and illicit drugs consumption during pregnancy by Ultra-High Performance Liquid Chromatography-High Resolution Mass Spectrometry (UHPLC-HRMS) target screening in Mexican women hair. Journal of Pharmaceutical and Biomedical Analysis, 2022, 211, 114607.	2.8	9

#	Article	IF	CITATIONS
73	Measurement of iodide and caffeine content in cellulite reductioncosmetic products sold in the European market. Analytical Methods, 2013, 5, 376-383.	2.7	8
74	High Performance Liquid Chromatography Tandem Mass Spectrometry Measurement of Bimatoprost, Latanoprost and Travoprost in Eyelash Enhancing Cosmetic Serums. Cosmetics, 2016, 3, 4.	3.3	8
75	Nonnucleoside Reverse Transcriptase Inhibitor Concentrations During Treatment Interruptions and the Emergence of Resistance: A Substudy of the ISS-PART Trial. AIDS Research and Human Retroviruses, 2010, 26, 541-545.	1.1	7
76	Is "light cannabis―really light? Determination of cannabinoids content in commercial products. Clinical Chemistry and Laboratory Medicine, 2020, 58, e175-e177.	2.3	7
77	Prevalence of Licit and Illicit Drugs Use during Pregnancy in Mexican Women. Pharmaceuticals, 2022, 15, 382.	3.8	7
78	SIMULTANEOUS LIQUID CHROMATOGRAPHIC DETERMINATION OF INDINAVIR, SAQUINAVIR, AND RITONAVIR IN HUMAN PLASMA WITH COMBINED ULTRAVIOLET ABSORBANCE AND ELECTROCHEMICAL DETECTION. Journal of Liquid Chromatography and Related Technologies, 2001, 24, 2325-2336.	1.0	6
79	The importance of biomarkers of fetal exposure to alcohol and psychotropic drugs in early diagnosis: A case report. Drug Testing and Analysis, 2018, 10, 895-898.	2.6	5
80	Novel fast ultraâ€performance liquid chromatography–tandem mass spectrometry (UHPLC–MS/MS) and extraction of ethylglucuronide in meconium samples. Drug Testing and Analysis, 2019, 11, 1471-1475.	2.6	5
81	Role of Neonatal Biomarkers of Exposure to Psychoactive Substances to Identify Maternal Socio-Demographic Determinants. Biology, 2021, 10, 296.	2.8	3
82	Systematic toxicological analysis of Indian herbal ready-to-chew pouches by gas chromatography mass spectrometry. Toxicologie Analytique Et Clinique, 2011, 23, 205-210.	0.1	3
83	Analytical Strategies to Disclose Repeated Consumption of New Psychoactive Substances by Hair Analysis. Current Pharmaceutical Biotechnology, 2018, 18, 834-839.	1.6	3
84	New Synthetic Opioids Use among Patients in Treatment for an Opioid Use Disorder in Barcelona. European Addiction Research, 2022, 28, 323-330.	2.4	3
85	Clinical features and risk factors associated with prenatal exposure to drugs of abuse. Anales De PediatrÃa (English Edition), 2021, 95, 307-320.	0.2	2
86	New Psychoactive Substances Consumption in Opioid-Use Disorder Patients. Biology, 2022, 11, 645.	2.8	2
87	Morphological Analysis of the Interaction of Charged Surfactant Vesicles (SVs) with Human Cultured Cells. Biotechnic and Histochemistry. 1999. 74. 77-84.	1.3	1